(Q36579814)

15 August 2017

1 reference

title

Accelerated immunotherapy schedules: review of efficacy and safety (English)

1 reference

15 August 2017

1 reference

Linda Cox

1

1 reference

15 August 2017

language of work or name

1 reference

1 August 2006

1 reference

Annals of Allergy, Asthma & Immunology

15 August 2017

published in

1 reference

15 August 2017

volume

97

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

126-37; quiz 137-40, 202

1 reference

Preventive aspects of immunotherapy: prevention for children at risk of developing asthma

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double-blind, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Determinants of patient compliance with allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Factors affecting compliance with allergen immunotherapy at a military medical center

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Systemic reactions from allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Survey of fatalities from skin testing and immunotherapy 1985-1989.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Specific ultrarush desensitization in Hymenoptera venom-allergic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Safety and efficacy of an imported fire ant rush immunotherapy protocol with and without prophylactic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Systemic reactions during the rush protocol in patients suffering from asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Systemic reactions occurring during immunotherapy with standardized pollen extracts

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Comparison between rush immunotherapy with a standardized allergen and an alum adjuved pyridine extracted material in grass pollen allergy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Pollen-specific rush immunotherapy: clinical efficacy and effects on antibody concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Immunotherapy with cat- and dog-dander extracts. II. In vivo and in vitro immunologic effects observed in a 1-year double-blind placebo study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Immunotherapy with cat- and dog-dander extracts. IV. Effects of 2 years of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Specific immunotherapy in inhalative allergy to rat epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Rush immunotherapy: experience with a one-day schedule

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Safety of rush immunotherapy to multiple aeroallergens in an adult population

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Suppression of the late asthmatic reaction by hyposensitization in asthmatic children allergic to house dust mite (Dermatophagoides pteronyssinus).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Decrease of skin and bronchial sensitization following short-intensive scheduled immunotherapy in mite-allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Clinical and biological evaluation of semi-rush and ordinary immunotherapy schemes in type I allergic respiratory diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Immunotherapy in patients allergic to cat and dog dander. I. Clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

A controlled trial of immunotherapy in insect hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Regimens of Hymenoptera venom immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Clustered immunotherapy with Yellow Jacket venom. Evaluation of the influence of time interval on in vivo and in vitro parameters.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Clustered schedules in allergen-specific immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Safety of venom immunotherapy administered by a cluster schedule

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Early effect of ultrarush venom immunotherapy on the IgG antibody response.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Rush immunotherapy results in allergen-specific alterations in lymphocyte function and interferon-gamma production in CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

Allergen rush immunotherapy increases interleukin (IL)-12 production and IL-12 receptor beta2 chain expression in patients with allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960003-8

7 January 2021

10.1016/S1081-1206(10)60003-8

Identifiers

DOI

1 reference

15 August 2017

1 reference